Fibulin-5: a novel biomarker for evaluating severity and predicting prognosis in patients with acute intracerebral haemorrhage.
The aim was to investigate relationships between serum fibulin-5 concentration and the severity or prognosis in patients with acute intracerebral haemorrhage (ICH). Consecutive ICH patients and healthy controls were included and clinical data were collected. National Institute of Health Stroke Scale (NIHSS) and Glasgow Coma Scale (GCS) were assessed at admission time within 3 days after bleeding. Cerebral haemorrhage volume was calculated and serum fibulin-5 concentration was measured at the same time. Multivariate linear regression analyses were performed to determine risk factors for serum fibulin-5 concentration and Spearman correlation coefficients were obtained to explore the relationships between fibulin-5 concentration and NIHSS or GCS scores. Patients were followed up for 3 months and the modified Rankin Scale was evaluated for all survivors. Receiver operating characteristic (ROC) curves were obtained to explore fibulin-5 concentration in predicting prognosis. Serum fibulin-5 concentration had increased in ICH patients compared with healthy controls (65.86 ± 26.39 μg/l vs. 40.66 ± 5.03 μg/l, P = 0.00) and was mainly influenced by haemorrhage volume (β = 0.905, P = 0.000) and extension to ventricles (β = 10.173, P = 0.097). Serum fibulin-5 concentration was positively correlated with NIHSS score (r = 0.511, P = 0.000) but inversely correlated with GCS score (r = -0.585, P = 0.000). Based on the ROC curves, the optimal cut-off point was 80.68 μg/l for death, and the sensitivity and specificity values of serum fibulin-5 were 77.8% and 93.2%, whilst the optimal cut-off point was 48.45 μg/l for poor prognosis and the sensitivity and specificity values were 86.4% and 54.1%, respectively. Serum fibulin-5 concentration can be regarded as a biomarker for evaluating disease severity and predicting prognosis in ICH patients.